Inhibition of endogenous ouabain by atrial natriuretic peptide is a guanylyl cyclase independent effect
| Autor: | Barbara J. Clark, John M. Hamlyn, Gulay Tegin, Rif S. El-Mallakh, Yonglin Gao |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Physiology
Vasodilator Agents Peptide Hormones Endogeny Blood Pressure Pharmacology Second Messenger Systems Biochemistry Vascular Medicine chemistry.chemical_compound Atrial natriuretic peptide Natriuretic peptide Medicine and Health Sciences Lipid Hormones Receptor Ouabain Cyclic GMP Aldosterone Oxadiazoles Multidisciplinary Organic Compounds Chemistry Second messenger system Physical Sciences cardiovascular system Medicine Steroids Biological Cultures hormones hormone substitutes and hormone antagonists Atrial Natriuretic Factor circulatory and respiratory physiology Research Article medicine.drug_class Science Radioimmunoassay Receptors Cell Surface Research and Analysis Methods Radioimmunoassays Natriuretic Peptide Cell Line Tumor Quinoxalines medicine Humans Secretion Immunoassays Cyclic guanosine monophosphate Organic Chemistry Chemical Compounds Biology and Life Sciences Cell Cultures Peptide Fragments Hormones Atrial Natriuretic Peptide chemistry Guanylate Cyclase Adrenal Cortex Immunologic Techniques Physiological Processes Receptors Atrial Natriuretic Factor |
| Zdroj: | PLoS ONE PLoS ONE, Vol 16, Iss 11 (2021) PLoS ONE, Vol 16, Iss 11, p e0260131 (2021) |
| ISSN: | 1932-6203 |
| Popis: | Background Endogenous ouabain (EO) and atrial natriuretic peptide (ANP) are important in regulation of sodium and fluid balance. There is indirect evidence that ANP may be involved in the regulation of endogenous cardenolides. Methods H295R are human adrenocortical cells known to release EO. Cells were treated with ANP at physiologic concentrations or vehicle (0.1% DMSO), with or without guanylyl cyclase inhibitor 1,2,4 oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). Cyclic guanosine monophosphate (cGMP), the intracellular second messenger of ANP, was measured by a chemiluminescent immunoassay and EO was measured by radioimmunoassay of C18 extracted samples. Results EO secretion is inhibited by ANP treatment, with the most prolonged inhibition (90 min vs ≤ 60 min) occurring at physiologic ANP concentrations (50 pg/mL). Inhibition of guanylyl cyclase with ODQ, also reduces EO secretion. The inhibitory effects on EO release in response to cotreatment with ANP and ODQ appeared to be additive. Conclusions ANP inhibits basal EO secretion, and it is unlikely that this is mediated through ANP-A or ANP-B receptors (the most common natriuretic peptide receptors) or their cGMP second messenger; the underlying mechanisms involved are not revealed in the current studies. The role of ANP in the control of EO synthesis and secretion in vivo requires further investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|